Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00920075
Other study ID # 5R01FD001847-05 REVISED
Secondary ID FD-R-001847-035R
Status Completed
Phase
First received
Last updated
Start date July 2009
Est. completion date October 2010

Study information

Verified date November 2010
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators earlier have shown that treatment of patients with juvenile osteoporosis with alendronate (Fosamax) for 12 months increased the bone density without side effects. In an open label study (10 patients) and double blind, crossover study (11 patients alendronate and 11 patients placebo), the investigators have further observed that alendronate increased the bone density significantly where as placebo (calcium and vitamin D) increased only minimally. These trials were completed. Thus, a post study is designed to evaluate the current status of the bone density and fractures after the patients discontinued the alendronate treatment. No treatment is involved.


Description:

With the availability of Dual Energy X-ray Absorptiometry (DXA), juvenile osteoporosis has been recognized and diagnosed in recent years. The disease results from either diminished bone formation or increased bone removal (resorption) resulting in low bone density and fractures. No specific drug therapy has been recommended for juvenile osteoporosis. In an open label study, we earlier have shown that alendronate treatment (10 patients) for 12 months increased bone density without side effects. Subsequently, in a double blind, crossover study, we have further confirmed that alendronate treatment (11 patients) increased bone density significantly whereas, placebo (11 patients with calcium and vitamin D), increased the bone density only minimally. There were no side effects. These patients were treated with alendronate only for 12 months and the clinical trials have been completed. We therefore, have designed a post study to evaluate the current status of the bone density and fracture history in the above participants after the discontinuation (1-6 years) of alendronate treatment. Available participants, who have completed the earlier study, will be scheduled for a one time clinic visit. Measurements include DXA bone density measurement of spine and hip, urinalysis and blood work. No treatment is involved.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date October 2010
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender All
Age group 8 Years to 21 Years
Eligibility Inclusion Criteria:

- Participated in our earlier clinical study;

- Completed the earlier open label or double blind study;

- Availability to participate in the post study;

- Male and female children who have earlier participated in our clinical trial; AND

- Parental consent (and patient assent after age 12 years) to participate in the study. Participant's consent for those who have completed 18 years of age and above at the time of clinic visit.

Exclusion Criteria:

- Not participated in our earlier clinical study;

- Not completed our earlier trials; OR

- Pregnancy.

Study Design


Intervention

Drug:
Alendronate (Fosamax)
Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (3)

Lead Sponsor Collaborator
Medical University of South Carolina FDA Office of Orphan Products Development, Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Key LL Jr, Ries W, Madyastha P, Reed F. Juvenile osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab. 2003 May;16 Suppl 3:683-6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bone Mineral Density (BMD) of the Lumbar Spine (Participants With Percentage Increase). Participants who earlier completed in our open labeled or double blind study of alendronate treatment for juvenile osteoporosis, were invited for one clinical visit. Bone density of spine was measured by DXA scan. Post study (1-6 yrs), one clinical visit
Secondary Bone Mineral Density (BMD) of the Hip (Participants With Percentage Increase). Participants who earlier completed in our open labeled or double blind study of alendronate treatment for juvenile osteoporosis, were invited for one clinical visit. Bone density of hip was measured by DXA scan. Post study (1-6 years), one clincial visit
Secondary Number of Participants With Fracture Participants who earlier completed in our open labeled or double blind study of alendronate treatment for juvenile osteoporosis, were invited for one clinical visit. Their bone densities of spine and hip were measured by DXA scan. During this visit, their fracture history was obtained. Post study (1-6 years), one clinical visit
See also
  Status Clinical Trial Phase
Completed NCT00137085 - Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation N/A
Completed NCT00152321 - Strategies Targeting Osteoporosis to Prevent Recurrent Fractures N/A
Completed NCT00235404 - Randomized Controlled Trial of Health Care to Elderly Patients. N/A
Completed NCT01127711 - Cohort of Swedish Men N/A
Completed NCT00060970 - Evaluating Muscle Function After Ankle Surgery N/A
Completed NCT02576730 - Functional Outcome Assessment After (Calcaneal) Trauma Surgey N/A
Completed NCT02074969 - Intramedullary Devices for the Treatment of Unstable Pertrochanteric Fractures N/A
Withdrawn NCT00355420 - Evaluation of the Change in Length of the Leg in Children After Treatment of Femur Fractures. Phase 2
Completed NCT00767780 - The Effect of a New Biomechanical Device N/A
Completed NCT00129142 - Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy Phase 3
Terminated NCT03367169 - Surgery of the Pilon Fractures N/A
Active, not recruiting NCT01452243 - Prevention of Falls and Fractures in Old People by Administration of Calcium and Vitamin D. Randomized Clinical Trial Phase 3
Completed NCT00545350 - Exercise Intervention to Prevent Fall-related Fractures and Other Injuries : The Ossébo Study N/A
Terminated NCT00387686 - A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures Phase 2/Phase 3
Completed NCT02292316 - Falls With Fracture : Role of Cognitive Disorders and Comparison With Bone Fragility N/A
Completed NCT01136616 - CT Analysis of Structural Buttresses in the Traumatised Nose Phase 2
Completed NCT02090972 - The Impact of Opioids in Fractures - a Case Control Study N/A
Recruiting NCT02237040 - A New Treatment Protocol for Paediatric Mandibular Condylar Fractures N/A
Completed NCT00872105 - Conservative Treatment Versus Operative Plate Fixation for Acute, Displaced Fractures of the Distal Clavicle N/A
Completed NCT00652548 - Use of Ultrasound to Evaluate Clavicle Fractures in Pediatric Patients N/A